Enterprise Solutions

INSIGHTS ON ENTERPRISE SOLUTIONS

Engineering The Next Wave Of CHO Performance
By combining improved productivity with speed and reliability, S-CHOice® 2G helps biopharmaceutical companies optimize their manufacturing strategies, reduce overall costs, and respond more effectively to market demands.
Catalent Capabilities Update March 2026: Analytical Services
A biologics analytics leader showcases development, testing, and characterization capabilities, emphasizing quality, regulatory compliance, and integrated support from discovery to commercialization.
Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy
A global CDMO specializing in cell and gene therapies, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.
Lonza Capabilities Update March 2026: Cell & Gene Therapy
A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

Accelerating Vector Construction-To-IND: Achieving A 9-Month Timeline Through Integrated Cell Line Development
3/19/2026

Uncover how tighter alignment between vector construction and cell banking improved development efficiency, strengthened risk management, and enhanced early-stage program outcomes.
Enhanced Biotherapeutic Protein Expression Using Advanced Vector Systems
3/18/2026

Learn how optimized expression vector design and data-driven strategies can significantly enhance product titre, quality, and long-term gene expression stability in GS-CHO cell-based manufacturing.
Improvements In ADC Efficacy And Stability
3/17/2026

Antibody-drug conjugates combine targeted antibodies with potent cytotoxic payloads, but increasing hydrophobicity challenges stability, manufacturability, and pharmacokinetics, driving interest in hydrophilic linker strategies to improve performance.
Building On Pittsburgh's Legacy To Industrialize Advanced Therapies
3/17/2026

Pittsburgh's industrial roots and growing biotech hub unite to scale advanced therapies through new purpose‑built biomanufacturing, automation, and workforce development.

Protein Degraders: From Discovery To Development

Leverage integrated platforms for targeted protein degradation and molecular glue solutions, from ligand identification to IND-enabling studies. Advanced screening and structural biology support accelerate discovery.
Pfizer Puurs: Sterile Injectables

Whether supporting established medicines or accelerating the launch of innovative treatments, the Puurs site delivers the scale, speed, and supply security needed to bring critical therapies to the patients who need them most.
Putting More Within Reach

A wearable subcutaneous injector is being developed to support delivery of large‑volume, complex biologic therapies, expanding options for patients needing advanced at‑home administration.
BD Neopak™ XtraFlow™ Glass Prefillable Syringe

A next‑generation injectable system uses shorter, thinner needles to reduce injection risk, lower force and time requirements, and improve comfort and usability for administering viscous formulations.
A Compact System That Delivers Sterile Tube Connections

Discover a compact, cordless system that delivers fast, sterile tube connections across multiple materials and sizes. Its long-lasting ribbon design reduces consumables while supporting reliable welds.